My Area

Languages:

Therakos e-learning platform

Health Economics

Cost Effectiveness

Cost-effectiveness analysis is an increasingly important tool for healthcare decision-making in the context of increasing budgetary constraints, an ever-increasing range of treatment options and the relatively high price of new treatments.^1-3

THERAKOS ECP Immunomodulation^TM has been shown to be cost effective in the treatment of both acute and chronic graft-versus-host disease (GvHD).^3-5

In addition, studies show that THERAKOS ECP Immunomodulation™ may help avoid the costs associated with immunosuppressing the patient.^3,5,6

In acute GvHD, THERAKOS ECP Immunomodulation^TM has been proven cost-effective in adults⁴

In chronic GvHD, THERAKOS ECP Immunomodulation^TM has been proven cost-effective in adults and children^3-5,7

References:
1. Hill SR. BMC Med. 2012;10:10; 2. Eichler HG, et al. Value Health. 2004;7(5):518-528; 3. Crespo C, et al. Clin Ther. 2012;34(8):1774-1787; 4. Walczak J, et al. Value Health. 2012;15:A349; 5. de Waure C, et al. Value Health. 2015;18(4):457-466; 6. Knobler R, et al. J Eur Acad Dermatol Venereol. 2014;28 Suppl 1:1-37; 7. THERAKOS™, data on file.

THERAKOS^TM CELLEX^TM Photopheresis System

Discover More

The Therakos Institute

Discover More

THERAKOS ECP Immunomodulation^TM

Discover More

About us

Discover More

Important Safety Information
For the Therakos^TM Photopheresis
Procedure

The THERAKOS^TM CELLEX^TM Photopheresis System is indicated for the administration of photopheresis. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

Indications

The THERAKOS^TM CELLEX^TM Photopheresis System is indicated for the administration of photopheresis. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients exhibiting idiosyncratic or hypersensitivity reactions to 8-methoxypsoralen/psoralen compounds
Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patiets who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TM Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure. Safety in children has not been established.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.

Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.

Treatment frequency exceeding labelling recommendations may result in anaemia.

Venous access carries a small risk of infection and pain.

Please refer to the THERAKOS^TM CELLEX^TM Photopheresis System Operator Manual for a complete list of warnings and precautions.

To report an adverse event please contact us at:
INTERNATIONAL FREEPHONE: 00800 84372567 (Available from most countries in Europe and Middle East and Africa)

ecphelp@therakos.com

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Contraindications

<p class="mb-2">Methoxsalen is contraindicated in: </p> <ul class="list-disc"> <li>Patients exhibiting idiosyncratic or hypersensitivity reactions to methoxsalen, psoralen compounds, or any of the excipients</li> <li>Patients with co-existing melanoma, basal cell or squamous cell skin carcinoma</li> <li>Patients who are pregnant, and sexually active men and women of childbearing potential unless adequate contraception is used during treatment</li> <li>Patients with aphakia because of the significantly increased risk of retinal damage due to the absence of a lens</li> </ul>

Warnings and Precautions

<ul class="list-disc"> <li>Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.</li> <li>Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.</li> <li>Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.</li> <li>Safety in children has not been established.</li> </ul> Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window. Safety in children has not been established. Refer to the Methoxsalen (20 micrograms/mL) labelling or the oral 8-methoxypsoralen dosage formulation package insert for more information on protecting the patient from light and a list of all warnings and precautions.

Important Safety Information
For the Therakos^TM Photopheresis
Procedure

Indications

The THERAKOS^TM CELLEX^TM Photopheresis System is indicated for the administration of photopheresis. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients exhibiting idiosyncratic or hypersensitivity reactions to 8-methoxypsoralen/psoralen compounds
Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patiets who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TM Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure. Safety in children has not been established.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projective injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD, an indication not approved in Canada. Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS^TM Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

Please refer to the THERAKOS^TM CELLEX^TM Photopheresis System Operator Manual for a complete list of warnings and precautions.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Contraindications

Methoxsalen is contraindicated in:

Patients exhibiting idiosyncratic or hypersensitivity reactions to methoxsalen, psoralen compounds, or any of the excipients
Patients with co-existing melanoma, basal cell or squamous cell skin carcinoma
Patients who are pregnant, and sexually active men and women of childbearing potential unless adequate contraception is used during treatment
Patients with aphakia because of the significantly increased risk of retinal damage due to the absence of a lens

Warnings and Precautions

Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.
Safety in children has not been established.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.